INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (the "Company") on May 6, 2024, covering events occurring on May 1, 2024. The filing details amendments to the previously announced merger agreement with NAYA Biosciences, Inc. ("NAYA") and a related Securities Purchase Agreement.
Key Financial Metrics and Agreements
The filing does not report standard financial performance metrics such as revenue, profit, or cash flow for a specific period. Instead, it outlines specific capital transaction terms:
- Merger Extension: The termination date for the Merger Agreement has been extended to June 30, 2024.
- Interim PIPE Definition: The agreement defines a two-phase funding requirement:
- Phase 1: Sale of Series A Preferred Stock under the amended Securities Purchase Agreement.
- Phase 2: A private offering of preferred stock at $5.00 per share to be consummated prior to the merger closing. Proceeds are intended to support fertility business activities for 12 months post-closing and cover past due accrued payables.
- Securities Purchase Agreement (SPA) Amendment: NAYA agreed to purchase the remaining 838,800 shares of Series A Preferred Stock at $5.00 per share.
- Initial Installments: Scheduled payments from May 10, 2024, through July 5, 2024, totaling $1,200,000 for 240,000 shares.
- Final Installment: The remaining 598,800 shares ($2,894,000) are to be purchased on or before the closing of the Merger Agreement.
Material Changes
The primary material change is the extension of the merger deadline and the restructuring of the funding timeline. The Company confirmed it remains free to secure additional third-party funding without NAYA's prior consent, provided terms are acceptable under SEC and Nasdaq regulations. Additionally, the Company may terminate the Merger Agreement if NAYA breaches covenants related to the Securities Purchase Agreement.
Outlook, Risks, and Contingencies
The filing indicates that the completion of the merger is contingent upon the successful consummation of the Phase 2 private offering prior to closing. The Company faces liquidity risks related to "past due accrued payables," which the Phase 2 funding is specifically designed to address. The extension of the merger deadline to June 30, 2024, introduces a time-bound contingency for closing the transaction.
Investor Verification Checklist
- Verify the execution of the scheduled SPA installment payments by NAYA starting May 10, 2024.
- Confirm the status of the Phase 2 private offering and whether the $5.00 per share price is being met.
- Monitor the Company's ability to resolve past due accrued payables as outlined in the Phase 2 funding purpose.
- Check for any announcements regarding the termination of the Merger Agreement if NAYA fails to perform its covenants.
- Review the full text of the Third Amendment (Exhibit 2.1) and SPA Amendment (Exhibit 10.1) for specific legal conditions not summarized here.